Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
Assessment of the number of days' treatment with semapimod necessary for efficacy, as
measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to
severe Crohn's disease (CD).